FDA panel to discuss Endo's oxymorphone

FDA's Anesthetic and Life Support Drugs and Drug Safety and Risk Management advisory committees will meet on Dec. 2 to discuss an NDA from Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) for an extended-release, crush-resistant formulation of oxymorphone to treat moderate to severe pain in patients requiring continuous opioid treatment for an extended period of time. The product, which has a PDUFA date of Jan. 7, 2011, is partnered with Gruenenthal Group (Aachen, Germany). Endo was down $0.03 to $36.74 on Friday. ...